Oss, July, 4th, 2016 – At the 24th congress of the European Association for Cancer Research (EACR), to be held in Manchester (U.K.) from 9 – 12 July, NTRC will present two posters, one on comparative cancer cell line profiling (OncolinesProfiler™), and one on target residence time and X-ray protein crystallography of TTK kinase inhibitors. Both posters will be presented on Sunday, July 10th, from 10:15 to 17:15 in the Central Hall of the Convention Centre, in the session ‘Experimental/Molecular Therapeutics, Pharmacogenesis I’.
Poster presentation on OncolinesProfiler™:
Title: “Comparative cancer cell line profiling differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors”
Abstract and poster board number: 580
Presenting author: Dr. Joost Uitdehaag
Poster presentation on TTK kinase inhibitor program:
Title: “The unique binding mode of NTRC 0066-0, a novel inhibitor of the spindle assembly checkpoint kinase TTK (Mps1), leads to long target residence time and potent antitumor activity”
Abstract and poster board number: 586
Presenting author: Dr. Guido Zaman
About NTRC
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, SynergyFinder™ and OncolinesProfiler™), target residence time measurements for protein kinases (ResidenceTimer™), and developing new enabling technologies, such as NFK GreenScreen™. In addition, NTRC develops own novel targeted therapies based on small molecules, such as selective inhibitors of TTK (Mps1) protein kinase for chromosomal unstable tumours and inhibitors of the tryptophan metabolizing enzymes IDO1 and TDO for cancer immunotherapy. For more information please visit www.ntrc.nl or contact info@ntrc.nl
